CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 39 filers reported holding CRISPR THERAPEUTICS AG in Q2 2017. The put-call ratio across all filers is 106.00 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $953,000 | +85.4% | 15,649 | +24.7% | 0.01% | +50.0% |
Q3 2019 | $514,000 | -2.5% | 12,545 | +12.5% | 0.00% | 0.0% |
Q2 2019 | $527,000 | +33.4% | 11,151 | +1.1% | 0.00% | +33.3% |
Q1 2019 | $395,000 | +33.0% | 11,034 | +6.0% | 0.00% | 0.0% |
Q4 2018 | $297,000 | -21.8% | 10,406 | +21.7% | 0.00% | 0.0% |
Q3 2018 | $380,000 | +104.3% | 8,551 | +110.9% | 0.00% | +50.0% |
Q2 2018 | $186,000 | 0.0% | 4,054 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $186,000 | +745.5% | 4,054 | +334.0% | 0.00% | – |
Q4 2017 | $22,000 | +100.0% | 934 | +47.3% | 0.00% | – |
Q3 2017 | $11,000 | +450.0% | 634 | +534.0% | 0.00% | – |
Q2 2017 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q1 2017 | $2,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |